Kumar et al. J Clin Gastroenterol Treat 2015, 1:1 ISSN: 2469-584X Journal of Clinical Gastroenterology and Treatment Case Report: Open Access Hormonal Therapy for GI Angiodysplasia: Out of Hope After Failure of the Scope? Ujjwal Kumar1*, Kevin Cowley1 and Frederick Weber2 1Tinsley Harrison Internal Medicine Residency Program, University of Alabama at Birmingham, Birmingham, AL, USA 2Division of Gastroenterology and Hepatology, University of Alabama at Birmingham Hospital, Birmingham, AL, USA *Corresponding author: Ujjwal Kumar, MD, Tinsley Harrison Internal Medicine Residency Program, 1720 2nd Ave South, BDB 327, Birmingham, AL 35294, USA, Tel: +1-205-934-2490, E-mail:
[email protected] Abstract of antiplatelet therapy. Endoscopic evaluations revealed diffuse GI angiodysplasia involving gastroduodenum, small bowel, and colon Angiodysplasia of the gastrointestinal (GI) tract can present with bleeding identified in multiple different regions of the small both diagnostic and therapeutic challenges. Despite the recent bowel on successive capsule endoscopies. Multiple endoscopic advances in endoscopy, many patients continue to suffer from therapies were performed via DBE between 2010 and 2013, and she recurrent bleeding. We report a remarkable case of a multi-year history of transfusion-requiring obscure overt recurrent GI bleeding, failed therapeutic trials of octreotide in escalated doses (after some refractory to multiple endoscopic therapies as well as both benefit with reduced hospitalizations for greater than 1 year) and octreotide and thalidomide. Upon initiation of hormonal therapy, the thalidomide (poorly tolerated and required discontinuation after patient’s bleeding completely resolved, with complete cessation of several months). From June 2012 through October 2013, melenic transfusion and procedure requirements for 18 months.